Study dovetails earlier research showing improved COVID-19 recovery outcomes in individuals with higher K2 status.
A newly published paper[1] in Biocatalysis and Agricultural Biotechnology from New Zealand researchers elucidates the association between K2 and recovery rates in individuals with COVID-19.
According to the authors, a “profound increase” in inactive matrix Gla protein (MGP) levels were observed in COVID-19 patients, indicating a poor K2 status and associated increased risk of mortality from comorbidities (e.g., obesity, diabetes, hypertension, and cardiovascular diseases).
MGP is dependent upon vitamin K2 menquinone-7 (MK-7) to become active, and the more circulating MGP that is active, the more calcification in arteries is inhibited. Vascular calcification is a process known to commence in elastin fibers, and elastin is a substantial player in ensuring tissues remain pliable and resilient. Elastic fibers are heavily present in lung tissue, where MGP, when activated, is considerably expressed – indicating the importance of MK-7 in supporting lung (pulmonary) function.
The researchers write: “Therefore, MK-7 deficiency can be a risk factor for increasing the severity of the COVID-19 disease, and SARS-CoV-2 infected patients with comorbid conditions tend to develop acute manifestations.”
Helping to build resilience to age-related conditions
This paper strengthens the concept that Vitamin K2 as MK-7 is a nutrient with substantial ability to protect pulmonary function during an active virus. It supports an earlier study published in April[2] that evaluated MK-7 in 123 patients with COVID-19 and 184 controls, revealing a link between vitamin K2 deficiency and disease severity.
“Evidence continues to mount that MK-7’s mechanism of action has a considerable impact on protecting human health,” said ex-NattoPharma Chief Medical Officer Dr. Hogne Vik. “Of course, a dietary supplement is not a cure or a treatment, but over time, MK-7 can fortify the body’s resilience to age-related conditions and viral infection. This is the second study that associates K2 status with outcomes in COVID-19 patients. More research in this area is warranted and necessary.”
Ex-NattoPharma ASA and its US subsidiary ex-NattoPharma USA, Inc. continue to lead the research endeavors into MK-7 (as MenaQ7®) as well as global MenaQ7® product development.
References:
1 Berenjian A, Sarabadani Z, “How menaquinone-7 deficiency influences mortality and morbidity among COVID-19 patients” Biocatalysis and Agricultural Biotechnology 29 (2020) 101792
2 Dofferhoff, A.S.; Piscaer, I.; Schurgers, L.J.; Walk, J.; van den Ouweland, J.M.; Hackeng, T.M.; Lux, P.; Maassen, C.; Karssemeijer, E.G.; Wouters, E.F.; Janssen, R. Reduced Vitamin K Status as A Potentially Modifiable Prognostic Risk Factor in COVID-19. Preprints 2020, 2020040457 (doi: 10.20944/preprints202004.0457.v1).
DISCOVER ALL OUR LATEST NEWS
Lynside® Forte Se+ for Skin Protection Against Sun Exposure
Selenium yeast boosts skin defenses against sun damage by fighting oxidative stress, supporting repair, and reducing inflammation for healthier, more resilient skin.
Successful Vital Nutrients Symposium:
Shaping the Future of Healthy Aging
The Vital Nutrients Symposium 2025, held in Kassel, Germany, offered an excellent platform to discuss age-related health, emphasizing emphasizing dietary supplements’ role in prolonging healthspan.
Groundbreaking Vitamin K2 Research Presented at the 7th Osteoporosis Congress in Padova (March 19-21, 2025)
Gnosis recently took an important step in advancing the scientific understanding of vitamin K2 by sponsoring the 7th Osteoporosis Congress in Padova, Italy. Supported by the Italian Ministry of Health, this event brought together esteemed experts in nephrology, osteoporosis, and bone health.
